BCM
PETX

BlueCrest Capital Management’s Aratana Therapeutics, Inc. PETX Stock Holding History

BlueCrest Capital Management’s Portfolio PETX Stock Details PETX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-11,049
Closed -$80K – 1201
2017
Q2 		$80K Buy
+11,049
New +$67.9K ﹤0.01% 834

Other funds holding PETX

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
GAI
General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return

BlueCrest Capital Management's PETX Position: Q3 2017 in Review

BlueCrest Capital Management sold out of Aratana Therapeutics, Inc. (PETX) in Q3 2017, closing a stake of 11,049 shares — an estimated $80K sold.

BlueCrest Capital Management first reported a position in PETX in Q2 2017 and held it in 1 quarter. The position peaked at $80K in Q2 2017. 96 funds tracked by Wall St. Rank hold PETX as of Q3 2017.

  • BlueCrest Capital Management reported no remaining Aratana Therapeutics, Inc. position as of Q3 2017 after selling out during the quarter.
  • BlueCrest Capital Management sold 11,049 Aratana Therapeutics, Inc. shares in Q3 2017, an estimated $80K.
  • BlueCrest Capital Management first reported a position in Aratana Therapeutics, Inc. in Q2 2017 and held it in 1 quarter.
  • BlueCrest Capital Management's Aratana Therapeutics, Inc. position peaked at $80K in Q2 2017.
  • 96 funds tracked by Wall St. Rank held Aratana Therapeutics, Inc. as of Q3 2017.

Based on BlueCrest Capital Management's 13F filing for Q3 2017, filed 14 Nov 2017.